Clinical trials: EGFR Mutation-positive Inoperable or Reccrent NSCLC

EGFR Mutation-positive Inoperable or Reccrent NSCLC

Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)

• Completed
• Age: 0 years and older
• Observational study
• Results posted

Secondary data collection study: safety and efficacy of VIZIMPRO under Japanese medical practice

Trial name

NCT04155541

Testing

dacomitinib hydrate

Where

Japan

Volunteers

40 people

Sponsor

Pfizer